Besides, imatinib, an inhibitor of KIT/PDGFRA kinase, is a standard therapy used to cure metastatic GIST; however, the low expression of c-kit oncoprotein in some GISTs could lead to the development of a therapeutic resistance [39]. Here, KIT is linked to gastrointestinal stromal tumor.